Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors

NANot yet recruitingINTERVENTIONAL
Enrollment

367

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Lung Cancer
Interventions
DRUG

chemotherapy plus TCM 1&ICIs plusTCM2 placebo

"In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang and Xu Ling. Package of granules is made into two types with functions such as tonifying the stomach and nourishing the blood recipe, benefiting Qi Yin and detoxification and resolving masses recipe. The herbal treatment is adapted to the syndromes.~Chemotherapy:Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin:administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs:Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab:administrated for patients with NSCLC requiring post-operative adjuvant therapy."

DRUG

chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo

"Chemotherapy:Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin:administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs:Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab:administrated for patients with NSCLC requiring post-operative adjuvant therapy."

Trial Locations (1)

200437

YueYang Hosptial of Intergrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

collaborator

Shanghai Chest Hospital

OTHER

collaborator

Fudan University

OTHER

collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

Ruijin Hospital

OTHER

lead

Shanghai University of Traditional Chinese Medicine

OTHER

NCT05834413 - Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors | Biotech Hunter | Biotech Hunter